$LYEL
Lyell Immunopharma, Inc.

2022 Q4 Form 10-Q Financial Statement

#000162828022028929 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $48.39M $3.000K $2.755M
YoY Change 1614.6% -99.89% 157.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $26.35M $26.08M $21.24M
YoY Change -17.33% 22.8% 56.53%
% of Gross Profit
Research & Development $45.34M $41.61M $31.43M
YoY Change 135.1% 32.37% 28.29%
% of Gross Profit
Depreciation & Amortization $5.041M $4.621M $4.091M
YoY Change 10.43% 12.96% 98.02%
% of Gross Profit
Operating Expenses $63.17M $66.44M $51.92M
YoY Change 25.44% 27.98% 36.93%
Operating Profit -$66.44M -$49.16M
YoY Change 35.14% 33.43%
Interest Expense $3.453M $2.251M $270.0K
YoY Change 969.04% 733.7% -75.36%
% of Operating Profit
Other Income/Expense, Net $2.934M -$3.817M $16.00K
YoY Change -6768.18% -23956.25% -42.86%
Pretax Income -$8.397M -$70.25M -$48.88M
YoY Change -89.97% 43.74% 36.83%
Income Tax
% Of Pretax Income
Net Earnings -$8.397M -$70.25M -$48.88M
YoY Change -89.97% 43.74% 36.83%
Net Earnings / Revenue -17.35% -2341800.0% -1774.05%
Basic Earnings Per Share -$0.28 -$0.20
Diluted Earnings Per Share -$0.03 -$0.28 -$203.8K
COMMON SHARES
Basic Shares Outstanding 249.3M shares 247.8M shares 239.4M
Diluted Shares Outstanding 248.3M shares 239.4M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $640.2M $648.1M $618.9M
YoY Change 4.12% 4.72%
Cash & Equivalents $123.6M $116.3M $393.5M
Short-Term Investments $516.6M $531.8M $225.4M
Other Short-Term Assets $11.14M $11.61M $12.23M
YoY Change -3.04% -5.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $651.3M $659.7M $631.1M
YoY Change 3.99% 4.53%
LONG-TERM ASSETS
Property, Plant & Equipment $123.0M $125.7M $115.9M
YoY Change 2.44% 8.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $115.0M $144.5M $401.0M
YoY Change -65.2% -63.96%
Other Assets $4.680M $2.914M $2.669M
YoY Change 34.37% 9.18%
Total Long-Term Assets $286.3M $317.5M $567.2M
YoY Change -42.87% -44.02%
TOTAL ASSETS
Total Short-Term Assets $651.3M $659.7M $631.1M
Total Long-Term Assets $286.3M $317.5M $567.2M
Total Assets $937.6M $977.3M $1.198B
YoY Change -16.84% -18.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.917M $4.795M $3.526M
YoY Change 22.14% 35.99%
Accrued Expenses $28.76M $23.57M $25.06M
YoY Change -1.04% -5.95%
Deferred Revenue $0.00 $11.19M $5.581M
YoY Change -100.0% 100.52%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.03M $51.22M $59.28M
YoY Change -20.78% -13.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.113M $4.227M $5.012M
YoY Change -9.92% -15.66%
Total Long-Term Liabilities $4.113M $4.227M $5.012M
YoY Change -9.92% -15.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.03M $51.22M $59.28M
Total Long-Term Liabilities $4.113M $4.227M $5.012M
Total Liabilities $104.3M $157.2M $211.9M
YoY Change -47.22% -25.78%
SHAREHOLDERS EQUITY
Retained Earnings -$767.5M -$759.1M -$500.7M
YoY Change 31.34% 51.62%
Common Stock $25.00K $25.00K $1.487B
YoY Change 4.17% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $833.3M $820.0M $986.5M
YoY Change
Total Liabilities & Shareholders Equity $937.6M $977.3M $1.198B
YoY Change -16.84% -18.45%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$8.397M -$70.25M -$48.88M
YoY Change -89.97% 43.74% 36.83%
Depreciation, Depletion And Amortization $5.041M $4.621M $4.091M
YoY Change 10.43% 12.96% 98.02%
Cash From Operating Activities -$40.27M -$37.10M -$25.53M
YoY Change 21.38% 45.32% -76.9%
INVESTING ACTIVITIES
Capital Expenditures $4.582M -$2.791M -$11.60M
YoY Change -144.62% -75.94% -41.18%
Acquisitions
YoY Change
Other Investing Activities $51.23M -$54.29M -$133.3M
YoY Change -180.51% -59.26% -21.65%
Cash From Investing Activities $46.65M -$57.09M -$144.9M
YoY Change -163.12% -60.6% -23.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 863.0K 4.760M -531.0K
YoY Change -88.34% -996.42% -1709.09%
NET CHANGE
Cash From Operating Activities -40.27M -37.10M -25.53M
Cash From Investing Activities 46.65M -57.09M -144.9M
Cash From Financing Activities 863.0K 4.760M -531.0K
Net Change In Cash 7.244M -89.43M -170.9M
YoY Change -107.27% -47.68% -43.09%
FREE CASH FLOW
Cash From Operating Activities -$40.27M -$37.10M -$25.53M
Capital Expenditures $4.582M -$2.791M -$11.60M
Free Cash Flow -$44.85M -$34.31M -$13.93M
YoY Change 95.8% 146.26% -84.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001806952
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40502
dei Entity Registrant Name
EntityRegistrantName
Lyell Immunopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1300510
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Haskins Way
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
695-0677
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
LYEL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
249325627 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116311000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293828000 usd
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
531821000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
320966000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11613000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11492000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
659745000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
626286000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
279000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
466000 usd
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
102519000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
283531000 usd
CY2022Q3 us-gaap Other Investments
OtherInvestments
42001000 usd
CY2021Q4 us-gaap Other Investments
OtherInvestments
47001000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125727000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
120098000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44084000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46541000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2914000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3483000 usd
CY2022Q3 us-gaap Assets
Assets
977269000 usd
CY2021Q4 us-gaap Assets
Assets
1127406000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4795000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3207000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23568000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
29057000 usd
CY2022Q3 lyel Success Payment Liabilities Current
SuccessPaymentLiabilitiesCurrent
11663000 usd
CY2021Q4 lyel Success Payment Liabilities Current
SuccessPaymentLiabilitiesCurrent
9486000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11191000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4988000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
51217000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46738000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64636000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66650000 usd
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37163000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
79665000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4227000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4566000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
157243000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
197619000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
249240000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
249240000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
242738000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
242738000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
25000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1589080000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1515748000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9996000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1623000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-759083000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-584362000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
820026000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
929787000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
977269000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1127406000 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11191000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
4988000 usd
CY2022Q3 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
37163000 usd
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
79665000 usd
CY2022Q3 us-gaap Revenues
Revenues
3000 usd
CY2021Q3 us-gaap Revenues
Revenues
2755000 usd
us-gaap Revenues
Revenues
36297000 usd
us-gaap Revenues
Revenues
7828000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41607000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31433000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
121156000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119408000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26084000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21241000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
90959000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57184000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1251000 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
758000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3544000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1526000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
66440000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
51916000 usd
us-gaap Operating Expenses
OperatingExpenses
208571000 usd
us-gaap Operating Expenses
OperatingExpenses
175066000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-66437000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-49161000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-172274000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-167238000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2251000 usd
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
270000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3600000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
842000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1068000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1047000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-117000 usd
CY2022Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
5000000 usd
CY2021Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 usd
us-gaap Impairment Of Investments
ImpairmentOfInvestments
5000000 usd
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3817000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
286000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2447000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
725000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-70254000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-48875000 usd
us-gaap Net Income Loss
NetIncomeLoss
-174721000 usd
us-gaap Net Income Loss
NetIncomeLoss
-166513000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1645000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-138000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8373000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-321000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71899000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49013000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-183094000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-166834000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
248320000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
248320000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
239384000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
239384000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
246285000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
246285000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100603000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100603000 shares
CY2022Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0 usd
CY2021Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2640000 usd
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
36299000 usd
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
7697000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
868042000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5127000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19123000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-367000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1645000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-70254000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
820026000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
929787000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9252000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63561000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
887000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-367000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8373000 usd
us-gaap Net Income Loss
NetIncomeLoss
-174721000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
820026000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1021955000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-39000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
529000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13042000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-138000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-48875000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
986474000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-292528000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
33198000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
391802000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1010968000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2043000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41023000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-321000 usd
us-gaap Net Income Loss
NetIncomeLoss
-166513000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
986474000 usd
us-gaap Net Income Loss
NetIncomeLoss
-174721000 usd
us-gaap Net Income Loss
NetIncomeLoss
-166513000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
63561000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
41023000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12979000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9059000 usd
us-gaap Impairment Of Investments
ImpairmentOfInvestments
5000000 usd
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 usd
lyel Fair Value Adjustment Of Success Payment Liabilities
FairValueAdjustmentOfSuccessPaymentLiabilities
2177000 usd
lyel Fair Value Adjustment Of Success Payment Liabilities
FairValueAdjustmentOfSuccessPaymentLiabilities
19343000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1067000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
199000 usd
lyel Non Cash Lease Expense
NonCashLeaseExpense
-1104000 usd
lyel Non Cash Lease Expense
NonCashLeaseExpense
1486000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-278000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1434000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-97000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-536000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
672000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6811000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1193000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5836000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
325000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36299000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7697000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
3331000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
10467000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-339000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
4121000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129288000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93036000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19694000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55236000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
346647000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
539541000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
308153000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
547066000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58188000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47711000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9252000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2043000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
887000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
367000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
391802000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9772000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
393845000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-177704000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
253098000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294294000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140872000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116590000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393970000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116311000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3563000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
393504000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
279000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
466000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116590000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393970000 usd
lyel Cash Received For Amounts Related To Tenant Improvement Allowances
CashReceivedForAmountsRelatedToTenantImprovementAllowances
3238000 usd
lyel Cash Received For Amounts Related To Tenant Improvement Allowances
CashReceivedForAmountsRelatedToTenantImprovementAllowances
11063000 usd
lyel Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
8136000 usd
lyel Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
5658000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5432000 usd
lyel Remeasurement Of Operating Lease Right Of Use Asset For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification
29000 usd
lyel Remeasurement Of Operating Lease Right Of Use Asset For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification
4078000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1010968000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain prior period amounts in the condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation.
CY2022Q3 lyel Cash Equivalents At Carry Value And Debt Securities Available For Sale Amortized Cost
CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost
738995000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (“GSK Agreement”) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together, “GSK”). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. On October 24, 2022, GSK provided notice to the Company of its decision to terminate the GSK Agreement. The termination is effective on December 24, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment increased revenue by $35.3 million, decreased net loss by $35.3 million and resulted in a $0.14 reduction in the Company’s basic and diluted net loss per common share for the nine months ended September 30, 2022.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations of Credit Risk and Off-balance Sheet RiskThe Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. These amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high-grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9999000 usd
CY2022Q3 lyel Cash Equivalents Fair Value Disclosure And Debt Securities Available For Sale
CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale
728999000 usd
CY2022Q3 lyel Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
94659000 usd
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
531821000 usd
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
102519000 usd
CY2022Q3 lyel Cash Equivalents Fair Value Disclosure And Debt Securities Available For Sale
CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale
728999000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
728999000 usd
CY2022Q3 lyel Success Payment Liabilities Fair Value Disclosure
SuccessPaymentLiabilitiesFairValueDisclosure
11663000 usd
CY2021Q4 lyel Cash Equivalents At Carry Value And Debt Securities Available For Sale Amortized Cost
CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost
876356000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1627000 usd
CY2021Q4 lyel Cash Equivalents Fair Value Disclosure And Debt Securities Available For Sale
CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale
874733000 usd
CY2021Q4 lyel Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
270236000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
320966000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
283531000 usd
CY2021Q4 lyel Cash Equivalents Fair Value Disclosure And Debt Securities Available For Sale
CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale
874733000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
507300000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
602900000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
126500000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2022Q3 us-gaap Other Investments
OtherInvestments
42000000 usd
CY2021Q4 us-gaap Other Investments
OtherInvestments
47000000 usd
CY2022Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
11663000 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
1067000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
875800000 usd
CY2021Q4 lyel Success Payment Liabilities Fair Value Disclosure
SuccessPaymentLiabilitiesFairValueDisclosure
9486000 usd
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
9486000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1822000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11018000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
11347000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
11859000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12209000 usd
CY2022Q3 lyel Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
48094000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
96349000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
27351000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.55
CY2022Q3 lyel Lessee Operating Lease Liability Tenant Improvement Allowance
LesseeOperatingLeaseLiabilityTenantImprovementAllowance
1523000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
67475000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2839000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64636000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
67475000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2300000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2400000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
7000000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
7100000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1300000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1400000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
3800000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
3700000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
194474431 shares
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
249239833 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
242738350 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19123000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13042000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63561000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41023000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
114900000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.05
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M2D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
41775179 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
142076000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9931442 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3512765 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2083979 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.07
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46109877 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M14D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
120296000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26446733 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M20D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
94486000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0232
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0079
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.856
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.787
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.33

Files In Submission

Name View Source Status
0001628280-22-028929-index-headers.html Edgar Link pending
0001628280-22-028929-index.html Edgar Link pending
0001628280-22-028929.txt Edgar Link pending
0001628280-22-028929-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_1.jpg Edgar Link pending
image_2.jpg Edgar Link pending
image_3.jpg Edgar Link pending
lyel-20220930.htm Edgar Link pending
lyel-20220930.xsd Edgar Link pending
lyel-20220930x10qxexx102.htm Edgar Link pending
lyel-20220930x10qxexx311.htm Edgar Link pending
lyel-20220930x10qxexx312.htm Edgar Link pending
lyel-20220930x10qxexx321.htm Edgar Link pending
lyel-20220930x10qxexx322.htm Edgar Link pending
lyel-20220930_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
lyel-20220930_def.xml Edgar Link unprocessable
lyel-20220930_lab.xml Edgar Link unprocessable
lyel-20220930_pre.xml Edgar Link unprocessable
lyel-20220930_cal.xml Edgar Link unprocessable
lyel-20220930_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable